Violeta Jardin: The Missing Link in TXA Use for Postpartum Hemorrhage
Violeta Jardin, General Manager at Haemoview Diagnostics, shared a post on LinkedIn:
”New from the SafePartum Maternal Safety Collaborative: an Expert Review Statement on TXA in obstetric hemorrhage via Vibha Mahendra — and it asks the question protocols often skip: which patients actually benefit?
The physiology is the key: TXA blocks the fibrin-dependent tPA route of plasmin generation, so it’s most rational in hyperfibrinolytic hemorrhage.
In dilutional coagulopathy it does nothing — you need fibrinogen, plasma, platelets. In consumptive coagulopathy it can worsen microvascular thrombosis. And benefit disappears (harm becomes possible) beyond the 3-hour window from birth.
The missing piece for bedside teams is phenotyping in real time, inside that window.
That’s exactly the gap APIRO Diagnostics Kft. TPA assay® closes — a whole-blood, tPA-challenged fibrinolysis read-out that flags hyperfibrinolysis at the bedside, so TXA is targeted to the patients who will actually respond, not given empirically.”
Stay updated with Hemostasis Today.
-
Aug 4, 2026, 17:14Edward Lee Carter: Not Every Stroke on a DOAC Is a DOAC Failure
-
Aug 4, 2026, 17:03Meghanath Yenni: Anticoagulant Reversal in Clinical Practice
-
Aug 4, 2026, 16:52Zain Tariq: TESLA One-Year Outcomes Published in JAMA
-
Aug 4, 2026, 16:31Javed Anees: When Rheumatic Heart Disease Causes Stroke
-
Aug 4, 2026, 14:43Moustafa Abdou: How to Recognize and Manage Hematologic Emergencies in Time
-
Aug 4, 2026, 14:40Majd A.AbuAlrob: Is TPA Beneficial for Spinal Infarction?
-
Aug 4, 2026, 14:27What Detecting Atrial Fibrillation After Stroke Really Means for Patient Care – International Journal of Stroke
-
Aug 4, 2026, 14:19Caitlin Raymond: Unvaccinated Blood Requests and Their Impact on Patient Safety
-
Aug 4, 2026, 13:50Hamish Aitken-Buck: New Insights Challenge the Role of Histidine Rich Glycoprotein in Thrombosis